The UK has approved a new drug product for glaucoma treatment, delivered with Novelia, Nemera's multidose preservative-free eyedropper

Thanks to its unique innovative design, Novelia® has been approved as packaging component and delivery system of multidose drug product formulated without preservatives.

“This approval sets an important milestone for Novelia®” said Fanny Sellier, Category Manager of Nemera. “We’re excited to make it easier for UK patients to use preservative-free glaucoma drugs”.

One way of keeping multi-dose eye droppers safe for patients is to add preservatives to the formulation. However, the use of preservatives can cause allergies or ocular irritation, and some can even cause a toxic response, damaging patients’ eyes[*]. Any such reactions are even more an issue for patients who rely on long term use of eye drops for chronic conditions, like glaucoma.

The alternative way to keep eye droppers contamination-free is by the intelligent use of technology. Rather than relying on the anti-microbial properties of preservatives to kill bacterias, the ideal approach is to prevent their entry into the bottle in the first place.

A viable alternative to the use of sterile filters for multi-dose preservative-free eye droppers is a non-return valve system used in conjunction with a silicone membrane to filter the incoming air. Novelia® : a multidose closing tip system avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment.

[*] Report of the International Dry Eye Workshop. Ocul Surf 2007; 5[2]; 65-204.

“There is no limit to Nemera’s ambition to serve patients. We already market devices in over 40 countries for millions of users. We’ll keep investing in new products and in state-of-the-art manufacturing equipment, to help even more patients with high quality devices all over the world.”

Marc Haemel, CEO

See also

Nemera's RetroNose enhances therapeutic efficacy of nasal treatments

The number of applications through the nasal route is expanding, either for local treatments (e.g. chronic rhinosinusitis) or for systemic treatments (e.g. migraine, etc.). The clinical efficacy of a nasal treatment depends on how it is deposited in the nose, because the pharmaceutical target (local, systemic, brain) is directly related to a specific nasal anatomical site. That’s why Nemera has collaborated with CEPR to develop a different and portable delivery technology called RetroNose for a better drug deposition in the distal region of the nose, without lung deposition.

e-Novelia wins the ‘Excellence in Pharma: Drug Delivery Devices’ award at CPhI Worldwide 2018

On October 9th, during the CPhI Pharma Awards Gala, e-Novelia®, Nemera’s electronic add-on for ophthalmic droppers, was celebrated as the best-in-class innovation displayed at the show for “Excellence in Pharma: Drug Delivery Devices”. e-Novelia®, Nemera’s smart ophthalmic add-on, has been designed to make patients’ life easier, by offering increased comfort and optimized adherence to their treatments.

Safelia 1ml and 2.25ml autoinjectors designed to be patient and syringe friendly

Nemera’s new generation 2-step autoinjector platforms are suitable for fluid to highly viscous injections. Safelia® has been designed to ease patient self-injection experience and to deliver even the most challenging drugs (viscous formulations up to several Centipoise, sustain released, concentrated, fragile and shear sensitive formulations, either in subcutaneous or intramuscular layers, on two platforms: up to 1ml or up to 2.25ml delivery).

  • Marine Silarbi
  • Product Info
  • English
  • Created 14 Sep 2016
  • Modified 22 Sep 2016
  • Hits 2042